A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to evaluate the safety and efficacy of glofitamab, as monotherapy and in combination with a standard chemoimmunotherapy regimen: rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric and young adult participants with relapsed and refractory (R/R) mature B-cell non-Hodgkin lymphoma (B-NHL).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 6 miesięcy do poniżej 18 lat (grupa A część 1 i B) lub poniżej 30 lat (grupa A część 2).
- •Potwierdzony typ chłoniaka B-komórkowego, który reaguje na leczenie celowane w CD20.
- •Choroba nawracająca lub oporna po wcześniejszym leczeniu.
- •Widoczne zmiany chorobowe (na podstawie badań obrazowych lub obecności komórek chłoniaka w szpiku).
- •Dobry ogólny stan zdrowia i wydolność organizmu.
- •Wystarczająca ilość komórek krwi oraz prawidłowe wyniki badań wątroby i nerek.
- •Negatywne wyniki testów na wirusy zapalenia wątroby typu B i C oraz HIV (lub stabilne leczenie antyretrowirusowe w przypadku HIV).
Simplified criteria — AI translation
Trial details
- Minimum age
- 6 Months
- Maximum age
- 30 Years
- Last updated (source)
- July 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (30)
Children's Hospital of Alabama
Birmingham, United States
UCSF Benioff Children's Hospital Oakland
Oakland, United States
Kaiser Permanente Oakland Medical Center
Oakland, United States
Kaiser Permanente - Roseville
Roseville, United States
Kaiser Permanente - Santa Clara
Santa Clara, United States
Johns Hopkins University
Baltimore, United States
Dana-Farber Cancer Institute
Boston, United States
Childrens Mercy Hosp & Clinics
Kansas City, United States
MSKCC
New York, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, United States
Queensland Children?s Hospital
South Brisbane, Australia
Perth Children's Hospital
Nedlands, Australia
Hospital Erasto Gaertner
Curitiba, Brazil
Graacc-Grupo de Apoio ao adolescente e a crianca com cancer
São Paulo, Brazil
West China Second University Hospital
Chengdu, China
Sun Yet-sen University Cancer Center
Guangzhou, China
Guangxi Cancer Hospital of Guangxi Medical University
Nanning, China
Fakultni nemocnice v Motole;Klinika detske hematologie a onkologie
Prague, Czechia
Rigshospitalet
København Ø, Denmark
Hôpital Pellegrin
Bordeaux, France
Gustave Roussy
Villejuif, France
Universitaetsklinikum Muenster
Münster, Germany
Semmelweis Egyetem II. sz. Gyermekgyogyaszati Klinika
Budapest, Hungary
IRCCS Ospedale Pediatrico Bambino Gesù
Rome, Italy
Ospedaliera Ospedale Infantile Regina Margherita
Turin, Italy
Ponadregionalne Centrum Onkologii Dzieci?cej ,,Przyladek Nadziei?;Klinika Transplantacji Szpiku, Onkologii i Hematologii Dzieciecej we Wroclawiu
Wroclaw, Poland
Seoul National University Hospital- Pediatric Site
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Infantil Universitario Niño Jesus
Madrid, Spain
Trial contact
Reference Study ID Number: CO43810 https://forpatients.roche.com/ No attachments to email below.
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.